The 2024 American Society of Clinical Oncology Annual Meeting (ASCO 2024) will take place in Chicago, USA, from May 31st to June 4th. As a major event in the cancer treatment community, it will reveal many important clinical research outcomes and the latest innovations. Antibody-drug conjugates (ADCs), which cleverly combine targeted antibody therapies with powerful […]
Folate receptor alpha (FRα), due to its differential expression in various tumor or cancer tissues compared to normal tissues, is considered an ideal druggable target. In the past, pharmaceutical companies have ventured into developing FRα-targeted therapies, including small molecule conjugates and monoclonal antibody drugs like Morphotek’s humanized monoclonal antibody farletuzumab, and Endocyte’s small molecule conjugate […]
In December 2023, GlaxoSmithKline (“GSK”) invested $1.71 billion to obtain the global exclusive rights for the development, production, and commercialization of HS-20093 from HANSON PHARAM (excluding mainland China, Hong Kong, Macau, and Taiwan). HS-20093 is a novel B7-H3 targeted antibody-drug conjugate (ADC) developed independently by HANSON PHARAM. Similarly, in April 2024, Macrogenics’ stock price surged […]
Antibody-drug conjugates (ADCs) have been one of the hottest areas in the biopharmaceutical industry in recent years. Pharmaceutical giants such as Pfizer, AbbVie, AstraZeneca, and Merck are investing billions of dollars in breakthrough technologies targeting cancer treatment. According to the latest report from the market intelligence company Evaluate, in 2023, the total value of ADC-focused […]
In March 2022, a study published in Nature Cancer highlighted Cadherin 17 (CDH17) as an ideal target for chimeric antigen receptor (CAR) T-cell therapy in gastrointestinal tumors (including gastric cancer, pancreatic cancer, and colorectal cancer) and neuroendocrine tumors (NETs). CDH17 swiftly gained attention across major news platforms, providing fresh insights into tumor-associated antigens and the […]
Since Ganymed unveiled the efficacy data of Zolbetuximab (IMAB362), the anti-Claudin18.2 monoclonal antibody, for the treatment of advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJ) at the 2016 ASCO conference, Claudin18.2 has emerged as a focal point for pharmaceutical companies eager to advance therapeutic options. These companies explore various technological routes, including monoclonal antibodies, bispecific antibodies, […]
In the previous article, we focused on the popular drug target for weight loss, G Protein-Coupled Receptor 75 (GPR75). This time, our topic is another emerging target for treating adult obesity, Activin A Receptor Type 2 (ActRII). Unlike currently approved weight loss drugs, which can reduce the weight of obese patients but often lead to […]
When it comes to weight loss medications, one cannot overlook the remarkable success of Semaglutide (GLP-1 weight loss drug), which has propelled the Danish biopharmaceutical company, Novo Nordisk, to new heights. According to Novo Nordisk’s financial report for 2023, Semaglutide sales reached $21.2 billion in 2023. On March 7th, Novo Nordisk’s stock price surged by […]
Mucin1 (MUC1), also known as MAM6 and EMA, is a surface mucin glycoprotein found to be highly expressed in epithelial-derived tumor tissues, such as lung cancer, pancreatic cancer, prostate cancer, epithelial ovarian cancer, and breast cancer. Its expression has been correlated with tumor metastasis and recurrence. Currently, MUC1 has attracted the attention of several pharmaceutical […]
When it comes to DLL3, people immediately think of Rova-T, the ADC drug targeting the DLL3 receptor that dashed AbbVie’s $5.8 billion expectations. AbbVie’s setback had once caused a decline in the enthusiasm for DLL3-targeted treatments. However, the spotlight returned when Amgen unveiled the DLL3/CD3 bispecific antibody Tarlatamab data at the 2023 ESMO conference. On […]